Clin2
NCT06756191Possibly a fitNot yet recruiting

Antifungal drugs for a serious lung infection

Pulmonary Mucormycosis

Treatments studied

Part of Infections, Lungs & breathing clinical trials.

This trial tests antifungal drugs in people with a rare but serious fungal infection in the lungs called mucormycosis. It aims to find which treatment works best and is safest for patients.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
312 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years old or older.
  • You have been diagnosed with a fungal lung infection called pulmonary mucormycosis.
  • You have not already been treated with amphotericin B for this infection for more than 5 days.
  • You are not allergic to azoles or amphotericin B.
  • Your liver function blood tests are not severely abnormal.
  • You do not have severe heart or liver failure, active bleeding from the lungs, recent heart attack or stroke, or are on a heart-lung bypass machine.
  • You are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07185503Recruiting
Testing two antifungal drugs for mucormycosis with blood cancer

This trial tests a combination of two antifungal medications (liposomal amphotericin B and posaconazole or isavuconazole) to treat a serious fungal infection called mucormycosis in people with blood cancers like leukemia or lymphoma. The goal is to see if this combination is safe and works well.

Dalian
NCT05406037Recruiting
Testing blood and tissue markers for invasive mucormycosis

This study looks for specific lab “biomarkers” in people with mucormycosis, a serious fungal infection. It compares results with people who have higher infection risk but no active infection, to help doctors diagnose and track this illness more accurately.

Lille, Hauts-de-France
NCT06178627Enrolling by invitation· Phase 4
Amphotericin B for non-HIV cryptococcal meningitis

This trial tests the drug amphotericin B for people with cryptococcal meningitis who do not have HIV. The goal is to see if this treatment is safe and effective.

Shanghai, Shanghai Municipality
NCT07725874Not yet recruiting
Liposomal amphotericin B for mold infections after liver transplant

This trial tests the safety and effectiveness of a medicine called liposomal amphotericin B for treating serious mold infections in liver transplant recipients. It compares this medicine to another antifungal called voriconazole, and may help find the best way to treat these infections after a liver transplant.

NCT06926569Not yet recruiting
High-dose antifungal plus HIV meds for fungal infection

This trial tests a single high dose of a potent antifungal medicine (liposomal amphotericin B) combined with a modern HIV treatment (B/F/TAF) for people with HIV who have a serious fungal infection called talaromycosis. The goal is to see if this short, powerful treatment works well and is safe.

NCT07337720Not yet recruiting
Liposomal amphotericin B for aspergillosis with liver problems

This trial tests a medication called liposomal amphotericin B for people with a serious fungal infection (aspergillosis) who also have liver problems. The goal is to see if this treatment is safe and effective for them.

Hear when a new Pulmonary Mucormycosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.